{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:53:00Z","timestamp":1783432380904,"version":"3.54.6"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Henan Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.neuroscience.2026.02.036","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T16:11:56Z","timestamp":1771690316000},"page":"141-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["How cytochrome P450 enzymes in humans are involved in Parkinson\u2019s disease: a literature review"],"prefix":"10.1016","volume":"600","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0685-8216","authenticated-orcid":false,"given":"Bingyi","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingzhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4190-0932","authenticated-orcid":false,"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.neuroscience.2026.02.036_b0005","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/03601230902997766","article-title":"An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes","volume":"44","author":"Abass","year":"2009","journal-title":"J. Environ. Sci. Health B"},{"issue":"30","key":"10.1016\/j.neuroscience.2026.02.036_b0015","doi-asserted-by":"crossref","first-page":"26978","DOI":"10.1074\/jbc.M111.249532","article-title":"Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone","volume":"286","author":"Anderson","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.02.036_b0020","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF03033137","article-title":"Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease","volume":"5","author":"Asanuma","year":"2003","journal-title":"Neurotoxicol. Res."},{"issue":"21","key":"10.1016\/j.neuroscience.2026.02.036_b0025","doi-asserted-by":"crossref","first-page":"15597","DOI":"10.1074\/jbc.M610893200","article-title":"Kinetic and structural analysis of the early oxidation products of dopamine","volume":"282","author":"Bisaglia","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.02.036_b0030","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/cts.12663","article-title":"Acetaminophen overdose as a potential risk factor for Parkinson\u2019s disease","volume":"12","author":"Bohler","year":"2019","journal-title":"Clin. Transl. Sci."},{"issue":"2\u20133","key":"10.1016\/j.neuroscience.2026.02.036_b0035","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejphar.2009.09.062","article-title":"The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: an in vitro study","volume":"626","author":"Bromek","year":"2010","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.02.036_b0040","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1471-4159.2011.07339.x","article-title":"Cytochrome P450 mediates dopamine formation in the brain in vivo","volume":"118","author":"Bromek","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2012.06.025","article-title":"Gene\u2013environment interactions in Parkinson\u2019s disease: specific evidence in humans and mammalian models","volume":"57","author":"Cannon","year":"2013","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.02.036_b0050","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/cts.12692","article-title":"Standardizing CYP 2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics working group","volume":"13","author":"Caudle","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fphar.2017.00239","article-title":"CYP2D6 phenotyping using urine, plasma, and saliva metabolic ratios to assess the impact of CYP2D6\u221710 on interindividual variation in a chinese population","volume":"8","author":"Chen","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.02.036_b0060","first-page":"1409","article-title":"Frequency of depressive disorders in Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"12","author":"Chendo","year":"2022","journal-title":"J Park Dis."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.02.036_b0065","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1177\/08919887221135556","article-title":"High frequency of depressive disorders and suicidal phenomena in late-stage Parkinso\u0144s disease - a cross-sectional study","volume":"36","author":"Chendo","year":"2023","journal-title":"J. Geriatr. Psychiatry Neurol."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.02.036_b0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1515\/dmdi-2011-0037","article-title":"Human cytochrome P450 4F3: structure, functions, and prospects","volume":"27","author":"Corcos","year":"2012","journal-title":"Dmdi"},{"issue":"2","key":"10.1016\/j.neuroscience.2026.02.036_b0075","article-title":"The cholesterol 24-hydroxylase CYP46A1 promotes \u03b1-synuclein pathology in Parkinson\u2019s disease","volume":"23","author":"Dai","year":"2025","journal-title":"Dubnau j, Ed. PLOS Biol."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.02.036_b0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11910-024-01339-w","article-title":"Epidemiology of Parkinson\u2019s disease: an update","volume":"24","author":"Deliz","year":"2024","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.02.036_b0085","first-page":"461","article-title":"The role of oxidative stress in Parkinson\u2019s disease","volume":"3","author":"Dias","year":"2013","journal-title":"J Park Dis."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.freeradbiomed.2016.10.008","article-title":"Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson\u2019s disease","volume":"101","author":"Doria","year":"2016","journal-title":"Free Radic. Biol. Med."},{"issue":"11","key":"10.1016\/j.neuroscience.2026.02.036_b0095","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Dorsey","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0100","doi-asserted-by":"crossref","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the parkinson pandemic. Brundin P, Langston JW, Bloem BR, eds. J Park Dis. 2018;8(s1):S3-S8. doi:10.3233\/JPD-181474.","DOI":"10.3233\/JPD-181474"},{"issue":"3","key":"10.1016\/j.neuroscience.2026.02.036_b0105","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ana.20051","article-title":"CYP2D6 polymorphism, pesticide exposure, and Parkinson\u2019s disease","volume":"55","author":"Elbaz","year":"2004","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.02.036_b0110","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ddr.21778","article-title":"Anatomical distribution and expression of CYP in humans: neuropharmacological implications","volume":"82","author":"Fanni","year":"2021","journal-title":"Drug Dev. Res."},{"issue":"11","key":"10.1016\/j.neuroscience.2026.02.036_b0115","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"16","author":"Feigin","year":"2017","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.neuroscience.2026.02.036_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044478","article-title":"Functional PstI\/RsaI polymorphism in CYP2E1 is associated with the development, progression and poor outcome of gastric cancer. hold GL, ed","volume":"7","author":"Feng","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.neuroscience.2026.02.036_b0125","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.tips.2011.08.005","article-title":"Cytochrome P450 enzymes in the brain: emerging evidence of biological significance","volume":"32","author":"Ferguson","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.02.036_b0130","first-page":"1693","article-title":"Independent and joint associations of tea consumption and smoking with Parkinson\u2019s Disease Risk in Chinese adults","volume":"12","author":"for the China Kadoorie Biobank (CKB) Collaborative Group, Nie J, Liu C","year":"2022","journal-title":"J. Park Dis."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.02.036_b0135","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2125.2000.00259.x","article-title":"Parkinson\u2019s disease and CYP1A2 activity","volume":"50","author":"Forsyth","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.02.036_b0140","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00228-006-0250-8","article-title":"Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping","volume":"63","author":"Frank","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.02.036_b0145","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13041-020-00584-7","article-title":"Distribution of Parkinson\u2019s disease associated RAB39B in mouse brain tissue","volume":"13","author":"Gao","year":"2020","journal-title":"Mol. Brain"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.02.036_b0150","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03256440","article-title":"Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals","volume":"10","author":"Garc\u00eda-Mart\u00edn","year":"2006","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0155","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Su\u00e1stegui WA, Ramos-Ch\u00e1vez LA, Rubio-Osornio M, et al. The role of CYP2E1 in the drug metabolism or bioactivation in the brain. Romero FJ, ed. Oxid Med Cell Longev. 2017;2017(1):4680732. doi:10.1155\/2017\/4680732.","DOI":"10.1155\/2017\/4680732"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.02.036_b0160","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.devcel.2009.11.010","article-title":"Neuronal Regulation of the Spatial Patterning of Neurogenesis","volume":"18","author":"Gonzalez-Quevedo","year":"2010","journal-title":"Dev. Cell"},{"key":"10.1016\/j.neuroscience.2026.02.036_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.105416","article-title":"Ligand-binding properties and catalytic activity of the purified human 24-hydroxycholesterol 7\u03b1-hydroxylase, CYP39A1","volume":"193","author":"Grabovec","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.02.036_b0170","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009871","article-title":"New molecular mechanism underlying myc\u2010mediated cytochrome P450 2E1 upregulation in apoptosis and energy metabolism in the myocardium","volume":"8","author":"Guan","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"37","key":"10.1016\/j.neuroscience.2026.02.036_b0175","doi-asserted-by":"crossref","first-page":"33711","DOI":"10.1074\/jbc.M205146200","article-title":"Oxidation of methoxyphenethylamines by cytochrome P450 2D6","volume":"277","author":"Guengerich","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.02.036_b0180","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1039\/C7TX00020K","article-title":"Toxicological implications of mitochondrial localization of CYP2E1","volume":"6","author":"Hartman","year":"2017","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1094265","article-title":"A CYPome-wide study reveals new potential players in the pathogenesis of Parkinson\u2019s disease","volume":"13","author":"Hartz","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.02.036_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108670","article-title":"Inhibition of 7\u03b1,26-dihydroxycholesterol biosynthesis promotes midbrain dopaminergic neuron development","volume":"27","author":"Hennegan","year":"2024","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.02.036_b0195","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-023-00676-7","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease \u2013 a key disease hallmark with therapeutic potential","volume":"18","author":"Henrich","year":"2023","journal-title":"Mol. Neurodegener."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.02.036_b0200","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.neuroscience.2026.02.036_b0205","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0006-2952(97)00172-X","article-title":"Specific binding of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl) piperazine (GBR-12935), an inhibitor of the dopamine transporter, to human CYP2D6","volume":"53","author":"Hiroi","year":"1997","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.02.036_b0210","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1006\/bbrc.1998.9232","article-title":"Dopamine formation from tyramine by CYP2D6","volume":"249","author":"Hiroi","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.02.036_b0215","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0741-8329(93)90063-T","article-title":"Ethanol-inducible cytochrome P4502E1: Genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease","volume":"10","author":"Ingelman-Sundberg","year":"1993","journal-title":"Alcohol"},{"issue":"5","key":"10.1016\/j.neuroscience.2026.02.036_b0220","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.3892\/mmr.2017.7569","article-title":"DhHP-6 attenuates cerebral ischemia-reperfusion injury in rats through the inhibition of apoptosis","volume":"16","author":"Ji","year":"2017","journal-title":"Mol. Med. Rep."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.02.036_b0225","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/life12040502","article-title":"Epigenome-wide analysis of DNA methylation in Parkinson\u2019s disease cortex","volume":"12","author":"Kaut","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.neuroscience.2026.02.036_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116442","article-title":"Artificial intelligence-driven drug repositioning uncovers efavirenz as a modulator of \u03b1-synuclein propagation: Implications in Parkinson\u2019s disease","volume":"174","author":"Kim","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0235","doi-asserted-by":"crossref","unstructured":"K\u00fcttner J, Grzegorzewski J, Tautenhahn HM, K\u00f6nig M. A physiologically based pharmacokinetic model for CYP2E1 phenotyping via chlorzoxazone. bioRxiv. Published online January 1, 2023:2023.04.12.536571. doi:10.1101\/2023.04.12.536571.","DOI":"10.1101\/2023.04.12.536571"},{"issue":"9","key":"10.1016\/j.neuroscience.2026.02.036_b0240","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1177\/0091270008319709","article-title":"Evaluation of a [13 C]-dextromethorphan breath test to assess CYP2D6 phenotype","volume":"48","author":"Leeder","year":"2008","journal-title":"J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.02.036_b0245","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.biochi.2012.09.025","article-title":"24S-hydroxycholesterol in plasma: a marker of cholesterol turnover in neurodegenerative diseases","volume":"95","author":"Leoni","year":"2013","journal-title":"Biochimie"},{"issue":"23","key":"10.1016\/j.neuroscience.2026.02.036_b0250","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.3390\/cells12232738","article-title":"Human embryonic stem cell-derived immature midbrain dopaminergic neurons transplanted in parkinsonian monkeys","volume":"12","author":"L\u00f3pez-Ornelas","year":"2023","journal-title":"Cells"},{"issue":"1\u20132","key":"10.1016\/j.neuroscience.2026.02.036_b0255","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.neuropharm.2011.03.007","article-title":"The monoamine oxidase (MAO) inhibitor tranylcypromine enhances nicotine self-administration in rats through a mechanism independent of MAO inhibition","volume":"61","author":"Lotfipour","year":"2011","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.neuroscience.2026.02.036_b0260","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1016\/j.drudis.2021.06.006","article-title":"Structural insights into understudied human cytochrome P450 enzymes","volume":"26","author":"Machalz","year":"2021","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.02.036_b0265","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40035-017-0099-z","article-title":"Current understanding of the molecular mechanisms in Parkinson\u2019s disease: Targets for potential treatments","volume":"6","author":"Maiti","year":"2017","journal-title":"Transl. Neurodegener."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.02.036_b0270","doi-asserted-by":"crossref","DOI":"10.2174\/1389450118666170125144557","article-title":"Cytochrome P450 structure, function and clinical significance: a review","volume":"19","author":"Manikandan","year":"2018","journal-title":"Curr. Drug Targets"},{"issue":"7","key":"10.1016\/j.neuroscience.2026.02.036_b0275","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1460-9568.2010.07142.x","article-title":"Cytochrome P450 2D6 enzyme neuroprotects against 1\u2010methyl\u20104\u2010phenylpyridinium toxicity in SH\u2010SY5Y neuronal cells","volume":"31","author":"Mann","year":"2010","journal-title":"Eur. J. Neurosci."},{"issue":"7","key":"10.1016\/j.neuroscience.2026.02.036_b0280","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.neuropharm.2008.07.017","article-title":"Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment","volume":"55","author":"Mann","year":"2008","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.neuroscience.2026.02.036_b0285","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.neurobiolaging.2011.08.014","article-title":"The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson\u2019s disease patients","volume":"33","author":"Mann","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuroscience.2026.02.036_b0290","first-page":"1","article-title":"Nicotine has a therapeutic window of effectiveness in a Drosophila melanogaster Model of Parkinson\u2019s disease","author":"Mannett","year":"2022","journal-title":"Aasly j, Ed. Park Dis."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.02.036_b0295","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/cns.13801","article-title":"Astrocytes expressing Vitamin D\u2010activating enzyme identify Parkinson\u2019s disease","volume":"28","author":"Mazzetti","year":"2022","journal-title":"CNS Neurosci. Ther."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.02.036_b0300","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0022-510X(97)00179-2","article-title":"The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson\u2019s disease: a case-control study and meta-analysis","volume":"153","author":"McCann","year":"1997","journal-title":"J. Neurol. Sci."},{"issue":"11","key":"10.1016\/j.neuroscience.2026.02.036_b0305","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1096\/fj.201600275R","article-title":"Effects of bile acids on neurological function and disease","volume":"30","author":"McMillin","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0310","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3389\/fnmol.2017.00225","article-title":"Implications of DNA methylation in Parkinson\u2019s disease","volume":"10","author":"Miranda-Morales","year":"2017","journal-title":"Front. Mol. Neurosci."},{"issue":"8","key":"10.1016\/j.neuroscience.2026.02.036_b0315","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.3390\/ijms19082245","article-title":"Vitamin D in neurological diseases: a rationale for a pathogenic impact","volume":"19","author":"Moretti","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.neuroscience.2026.02.036_b0320","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/nan.12757","article-title":"Neurodegenerative movement disorders: an epigenetics perspective and promise for the future","volume":"47","author":"Murthy","year":"2021","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.02.036_b0325","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00702-009-0221-1","article-title":"Cytochrome P450 2E1 gene polymorphisms\/haplotypes and Parkinson\u2019s disease in a Swedish population","volume":"116","author":"Niazi Shahabi","year":"2009","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0330","doi-asserted-by":"crossref","first-page":"585","DOI":"10.18433\/jpps30622","article-title":"Inhibitory and stimulatory effects of selective serotonin reuptake inhibitors on cytochrome P450 2D6-mediated dopamine formation from p-tyramine","volume":"22","author":"Niwa","year":"2019","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0335","doi-asserted-by":"crossref","first-page":"135","DOI":"10.18433\/jpps29673","article-title":"Effect of cytochrome P450 (CYP) 2D6 genetic polymorphism on the inhibitory action of antidepressants on CYP2D6-mediated dopamine formation from p-tyramine","volume":"21","author":"Niwa","year":"2018","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0340","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.freeradbiomed.2015.06.036","article-title":"New aspects of 24(S)-hydroxycholesterol in modulating neuronal cell death","volume":"87","author":"Noguchi","year":"2015","journal-title":"Free Radic. Biol. Med."},{"issue":"7","key":"10.1016\/j.neuroscience.2026.02.036_b0345","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/FPC.0b013e32832e0e97","article-title":"Cytochrome P450 2D6","volume":"19","author":"Owen","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"issue":"6","key":"10.1016\/j.neuroscience.2026.02.036_b0350","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3892\/mmr.2021.12492","article-title":"Diallyl sulfide protects against dilated cardiomyopathy via inhibition of oxidative stress and apoptosis in mice","volume":"24","author":"Pang","year":"2021","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.02.036_b0355","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1038\/s41467-023-38215-z","article-title":"A pesticide and iPSC dopaminergic neuron screen identifies and classifies Parkinson-relevant pesticides","volume":"14","author":"Paul","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.02.036_b0360","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primer."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.02.036_b0365","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1468-1331.2011.03353.x","article-title":"Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson\u2019s disease: ADORA2A and CYP1A2 variants and PD risk","volume":"18","author":"Popat","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.02.036_b0370","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.3390\/ijms24032038","article-title":"Spotlight on CYP4B1","volume":"24","author":"R\u00f6der","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.02.036_b0375","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.3390\/molecules18033028","article-title":"Biotransformation of isoflavone using enzymatic reactions","volume":"18","author":"Roh","year":"2013","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.02.036_b0380","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/157488407779422302","article-title":"The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance","volume":"2","author":"Rosemary","year":"2007","journal-title":"Curr. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.02.036_b0385","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.taap.2004.12.027","article-title":"CYP2S1: a short review","volume":"207","author":"Saarikoski","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.02.036_b0390","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/1531-8257(199903)14:2<230::AID-MDS1005>3.0.CO;2-6","article-title":"CYP2D6 polymorphism and Parkinson\u2019s disease susceptibility","volume":"14","author":"Sabbagh","year":"1999","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.neuroscience.2026.02.036_b0395","doi-asserted-by":"crossref","first-page":"698","DOI":"10.2174\/1389200222666210729115151","article-title":"Unveiling the role of cytochrome P450 (2E1) in human brain specifically in Parkinson\u2019s disease - literature review","volume":"22","author":"Shah","year":"2021","journal-title":"Curr. Drug Metab."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.02.036_b0400","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/syn.20505","article-title":"Cytochrome P450 2E1 in the substantia nigra: relevance for dopaminergic neurotransmission and free radical production","volume":"62","author":"Shahabi","year":"2008","journal-title":"Synapse"},{"issue":"4","key":"10.1016\/j.neuroscience.2026.02.036_b0405","first-page":"22","article-title":"Bridging the genetical environmental gap in Parkinson\u2019s disease through epigenetics","volume":"2","author":"Shueb","year":"2016","journal-title":"J Clin Epigenet."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.02.036_b0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson disease epidemiology, pathology, genetics, and pathophysiology","volume":"36","author":"Simon","year":"2020","journal-title":"Clin. Geriatr. Med."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.02.036_b0415","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/jcsm.13022","article-title":"A disease\u2010associated missense mutation in CYP4F3 affects the metabolism of leukotriene B4 via disruption of electron transfer","volume":"13","author":"Smeets","year":"2022","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"issue":"10","key":"10.1016\/j.neuroscience.2026.02.036_b0420","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1007\/s00018-021-03802-0","article-title":"Oxidative stress and impaired oligodendrocyte precursor cell differentiation in neurological disorders","volume":"78","author":"Spaas","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.02.036_b0425","first-page":"356","article-title":"Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism","volume":"1851","author":"Spector","year":"2015","journal-title":"Biochim. Biophys. Acta BBA \u2013 Mol. Cell Biol. Lipids"},{"issue":"2","key":"10.1016\/j.neuroscience.2026.02.036_b0430","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/mds.28850","article-title":"Re\u2010analysis of the STEADY\u2010PD II Trial\u2014evidence for slowing the progression of Parkinson\u2019s disease","volume":"37","author":"Surmeier","year":"2022","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.neuroscience.2026.02.036_b0435","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/FPC.0b013e3282f09265","article-title":"Association between caffeine intake and risk of Parkinson\u2019s disease among fast and slow metabolizers","volume":"17","author":"Tan","year":"2007","journal-title":"Pharmacogenet. Genomics"},{"issue":"14","key":"10.1016\/j.neuroscience.2026.02.036_b0440","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.3390\/nu14142781","article-title":"Nutrition and gut\u2013brain pathways impacting the onset of Parkinson\u2019s Disease","volume":"14","author":"Terenzi","year":"2022","journal-title":"Nutrients"},{"issue":"20","key":"10.1016\/j.neuroscience.2026.02.036_b0445","first-page":"60","article-title":"Pesticides and Parkinson\u2019s disease: a potential hazard in agricultural communities","volume":"5","author":"Thakolwiboon","year":"2017","journal-title":"Southwest Respir Crit Care Chron."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0450","unstructured":"The Human Cytochrome P450 (CYP) Allele Nomenclature Database. https:\/\/www.pharmvar.org\/htdocs\/archive\/index_original.htm. Accessed 21 March 2024."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2019.108216","article-title":"Novel insights into oxidation of fatty acids and fatty alcohols by cytochrome P450 monooxygenase CYP4B1","volume":"679","author":"Thesseling","year":"2020","journal-title":"Arch. Biochem. Biophys."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.02.036_b0460","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/j.1471-4159.2004.02449.x","article-title":"A novel lipopolysaccharide\u2010modulated Jun binding repressor in intron 2 of CYP2E1","volume":"89","author":"Tindberg","year":"2004","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.02.036_b0465","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson\u2019s disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.02.036_b0470","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/jnc.15154","article-title":"The multi\u2010faceted role of mitochondria in the pathology of Parkinson\u2019s disease","volume":"156","author":"Trinh","year":"2021","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.02.036_b0475","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1007\/s12035-016-9938-7","article-title":"Monocrotophos induces the expression of xenobiotic metabolizing cytochrome P450s (CYP2C8 and CYP3A4) and Neurotoxicity in human brain cells","volume":"54","author":"Tripathi","year":"2017","journal-title":"Mol. Neurobiol."},{"issue":"12","key":"10.1016\/j.neuroscience.2026.02.036_b0480","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1007\/s11064-017-2384-8","article-title":"Cytochrome P450 2D6 and Parkinson\u2019s disease: polymorphism, metabolic role, risk and protection","volume":"42","author":"Ur Rasheed","year":"2017","journal-title":"Neurochem. Res."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.02.036_b0485","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1471-4159.2004.02720.x","article-title":"Involvement of cytochrome P450 2E1 in the 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine\u2010induced mouse model of Parkinson\u2019s disease","volume":"91","author":"Vaglini","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0490","first-page":"7","article-title":"Acetaldehyde and parkinsonism: role of CYP450 2E1","author":"Vaglini","year":"2013","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0495","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.804261","article-title":"Methylated cytochrome P450 and the solute carrier family of genes correlate with perturbations in bile acid metabolism in Parkinson\u2019s disease","volume":"16","author":"Vishweswaraiah","year":"2022","journal-title":"Front. Neurosci."},{"issue":"7","key":"10.1016\/j.neuroscience.2026.02.036_b0500","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10654-011-9574-5","article-title":"Parkinson\u2019s disease risk from ambient exposure to pesticides","volume":"26","author":"Wang","year":"2011","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0505","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejphar.2013.12.025","article-title":"The endogenous substrates of brain CYP2D","volume":"724","author":"Wang","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.02.036_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154911","article-title":"Nervonic acid improves liver inflammation in a mouse model of Parkinson\u2019s disease by inhibiting proinflammatory signaling pathways and regulating metabolic pathways","volume":"117","author":"Wang","year":"2023","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.neuroscience.2026.02.036_b0515","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/oxfordjournals.jbchem.a124526","article-title":"Different regulation and expression of the human CYP2E1 gene due to the Rsal polymorphism in the 5\u2019-flanking region1","volume":"116","author":"Watanabe","year":"1994","journal-title":"J. Biochem. (Tokyo)"},{"issue":"11","key":"10.1016\/j.neuroscience.2026.02.036_b0520","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00702-002-0721-8","article-title":"Genetic polymorphism of the CYP2E1 gene and susceptibility to Parkinson\u2019s disease in Taiwanese","volume":"109","author":"Wu","year":"2002","journal-title":"J. Neural Transm."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.02.036_b0525","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3724\/abbs.2023012","article-title":"Cooperation between NSPc1 and DNA methylation represses HOXA11 expression and promotes apoptosis of trophoblast cells during preeclampsia","volume":"55","author":"Xie","year":"2023","journal-title":"Acta Biochim. Biophy. Sin."},{"issue":"S1","key":"10.1016\/j.neuroscience.2026.02.036_b0530","doi-asserted-by":"crossref","first-page":"43","DOI":"10.37231\/ajmb.2022.6.S1.521","article-title":"Association between occupational toxicity exposure to pesticides and Parkinson\u2019s disease among adults: systematic review and meta-analysis","volume":"6","author":"Yahya","year":"2022","journal-title":"Asian J. Med. Biomed."},{"issue":"7","key":"10.1016\/j.neuroscience.2026.02.036_b0535","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/pgs-2017-0033","article-title":"Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing","volume":"18","author":"Yang","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1016\/j.neuroscience.2026.02.036_b0540","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/BF02256117","article-title":"Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes","volume":"10","author":"Yeh","year":"2003","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.02.036_b0545","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40035-023-00378-6","article-title":"Role of dopamine in the pathophysiology of Parkinson\u2019s disease","volume":"12","author":"Zhou","year":"2023","journal-title":"Transl. Neurodegener."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226001399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226001399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:48:45Z","timestamp":1777556925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452226001399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":108,"alternative-id":["S0306452226001399"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.02.036","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How cytochrome P450 enzymes in humans are involved in Parkinson\u2019s disease: a literature review","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.02.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}